Show notes
Send a text
This episode opens the year with one of the most consequential—and complicated—weeks in GLP-1 obesity medicine.
We break down three stories that, taken together, reveal why patients are increasingly reading past headlines and demanding accountability from the industry.
First, we examine early-phase trial data from Arrowhead Pharmaceuticals, after headlines claimed its experimental INHBE-targeting therapy “nearly doubled” the weight loss of Zepbound. We walk through what the data actually showed, why the comparison was misleading, how trial design and dosing matter, and why Phase 1 results should never be treated as superiority claims.
Next, we turn to a major access milestone: the official launch of oral Wegovy, the first FDA-approved GLP-1 pill for obesity from Novo Nordisk. We discuss how this pill differs from compounded oral semaglutide, why its pricing strategy is so disruptive, and what this launch means for people who have avoided injectable medications. We also explore how direct-to-consumer access, telehealth partnerships, and retail pharmacy distribution signal a broader shift in how obesity care is being delivered.
Finally, we address the most ironic—and uncomfortable—story of the week: manufacturing quality concerns involving branded Wegovy pens, reported to include biological particulate matter, at the same time Novo Nordisk continues a years-long public and legal campaign against compounded GLP-1 medications on safety grounds. We discuss FDA inspection history, the acquisition of Catalent, and why credibility depends on consistency—especially when millions of patients are paying close attention.
This episode isn’t anti-pharma or pharma-friendly. It’s patient-first.
And it asks a simple question: Who do we trust when science, marketing, access, and manufacturing all collide at once?
Episode Timestamps
00:00 — Why this first episode of 2026 matters
02:10 — Hair found in Wegovy pens and why patients notice hypocrisy
06:15 — Arrowhead trial headlines vs. what the data actually shows
11:40 — Why tirzepatide dosing and trial design matter
17:30 — What INHBE targeting may actually be good for (and what it’s not)
21:45 — Sponsor: SHED and access pathways for obesity care
25:10 — Oral Wegovy officially launches: what’s different this time
30:20 — How the Wegovy pill works and why bioavailability matters
35:40 — Pricing, telehealth, Costco, and direct-to-consumer access
41:50 — Why pills lower barriers for millions of patients
46:10 — Manu
🤝 Visit Our Sponsors!
OTPLinks.com
Decoding GLP-1 Book
Decoding GLP-1: A Guide for Friends and Family of Those On The Pen
Buy Here: https://amzn.to/3Dc66d4
MY WORK RELIES ON YOUR GENEROSITY, WAYS TO SUPPORT:
Venmo: OnThePen
Ca$h App: ManOnMounjaro
BECOME A MEMBER:
https://www.youtube.com/channel/UCDocQ-4IhVS3ihy_dW7nSKw/join
👉 My Amazon Affiliate Store:
https://www.amazon.com/shop/manonthemounjaroonthepen
WATCH MORE!
📺 We're Live M/W/F at 11 central: onthepen.tv
📲 Contact Me: dave@onthepen.com
Thank you for tuning in! If you found this content valuable, make sure to like, share, and subscribe to my youtube channel for more updates on GLP-1, obesity, type 2 diabetes, and the latest news on Mounjaro, Zepbound, Wegovy, and Ozempic. Stay informed and entertained with my unique blend of breaking news, humor, and my personal journey. For in-depth articles and resources, visit onthepen.com.
Our TOPPODCAST Picks 
Stay Connected
